This aggressive prostate cancer finally has targeted treatment — AstraZeneca wins FDA nod

AstraZeneca Plc AZN received two significant regulatory updates from the U.S. Food and Drug Administration, with its cancer ...
Medscape

Fuzuloparib Add-On Improves Metastatic Prostate Cancer rPFS

Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.
Fierce Pharma

ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win

Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer.  | After winning a broader FDA label in metastatic castration-resistant prostate cancer, ...
pharmaphorum

After Pluvicto: Alpha radiopharma and prostate cancer

There are around 46,000 new cases of prostate cancer each year in England and Wales, with 13% of these cases showing signs of ...
Targeted Oncology

FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient Prostate Cancer

The FDA has approved capivasertib (Truqap) in combination with abiraterone acetate (Zytiga) and prednisone for adults with ...
Medscape

FDA Advisors Split on Regimens for Breast, Prostate Cancers

In its first meeting in 9 months, the FDA’s Oncologic Drugs Advisory Committee (ODAC) backed a novel regimen for certain patients with prostate cancer but voted against recommending a new treatment ...

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...